Streetbeat News

Earnings

SRRK

Scholar Rock Holding (NASDAQ:SRRK) reported Q3 2023 losses of $(0.53) per share, missing the analyst consensus estimate of $(0.52) by 1.92 percent. This is a 3.64 percent increase over losses of $(0.55) per share from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

November 07, 2023 | 12:25 pm

ARVN

Arvinas has announced that its Q3 cash, cash equivalents, restricted cash, and marketable securities total around $1B. The company believes this is sufficient to fund its planned operating expenses and capital expenditure requirements until 2026.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:24 pm

ARVN

Arvinas (NASDAQ:ARVN) reported Q3 losses of $(1.18) per share, beating the analyst consensus estimate of $(1.57) by 24.84%. However, the company's quarterly sales of $34.60 million missed the analyst consensus estimate of $40.51 million by 14.59%. This represents a 4.22% increase over sales of $33.20 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:22 pm

HAIN

Hain Celestial Group (NASDAQ:HAIN) reported Q1 adjusted losses of $(0.04) per share, beating the analyst consensus estimate of $(0.06) by 33.33%. However, the company's quarterly sales of $425.03M missed the analyst consensus estimate of $431.32M by 1.46%. This represents a 140% decrease in earnings and a 3.26% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:22 pm

TAC

TransAlta (NYSE:TAC) reported Q3 sales of $758.00 million, beating the analyst consensus estimate of $535.90 million by 41.44 percent. This represents a 6.43 percent increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:21 pm

ITOS

ITeos Therapeutics reported Q3 losses of $(0.90) per share, beating the analyst consensus estimate of $(1.20) by 25 percent. This represents a 3100 percent decrease over earnings of $0.03 per share from the same period last year. The company's cash, cash equivalents, and investments position was $644.9M, expected to provide runway through 2026.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:21 pm

PWP

Perella Weinberg (NASDAQ:PWP) reported Q3 2023 earnings of $0.12 per share, beating the analyst consensus estimate of $0.05 by 140%. However, this is a 53.85% decrease from the same period last year. The company also reported quarterly sales of $139.00 million, beating the estimate of $129.93 million by 6.98%, but this is a 4.39% decrease from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

November 07, 2023 | 12:20 pm

DTIL

Precision BioSciences reported a Q3 cash balance of $122.2M, which is expected to provide an extended cash runway through the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:19 pm

DTIL

Precision BioSciences (NASDAQ:DTIL) reported Q3 losses of $(0.07) per share, beating the analyst consensus estimate of $(0.17) by 58.82%. The company also reported quarterly sales of $13.12 million, surpassing the analyst consensus estimate of $8.60 million by 52.56%. Both figures represent significant increases over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:18 pm

ADCT

ADC Therapeutics has projected a continued decrease in total operating expenses for FY23 and FY24 compared to FY22. The company also expects its cash runway to extend into the middle of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:17 pm